Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;39(11):2231-2237.
doi: 10.1038/s41433-025-03847-6. Epub 2025 May 15.

Correlation of retino-choroidal thickness and vascular metrics with drusen volume as a severity marker of age-related macular degeneration

Elham Sadeghi  1 , Anne Schulman  1 , Sharat Chandra Vupparaboina  2 , Sumit Randhir Singh  3 , Nasiq Hasan  1 , Sandeep Chandra Bollepalli  1 , Kiran Kumar Vupparaboina  1 , Jose Alain Sahel  1 , Andrew W Eller  1 , Jay Chhablani  4
Affiliations

Correlation of retino-choroidal thickness and vascular metrics with drusen volume as a severity marker of age-related macular degeneration

Elham Sadeghi et al. Eye (Lond). 2025 Aug.

Abstract

Purpose: To assess retinal vascular perfusion and choroidal vascularity biomarkers correlated with drusen volume and severity of age-related macular degeneration (AMD).

Methods: Patients underwent swept-source optical coherence tomography angiography (SS-OCTA) (PlexElite-9000). Eyes with geographic atrophy or neovascular AMD were excluded. Retinal thickness, retinal perfusion including superficial (SCP) and deep capillary plexuses (DCP), foveal avascular zone (FAZ), drusen volume, choroidal thickness (ChT) and choroidal vascularity index (CVI) were assessed through the Advanced Research and Innovation Network. Linear mixed model and Spearman test were used for statistical analysis.

Results: We assessed 81 eyes from 57 subjects (34 early-stage, 47 intermediate-stage AMD). The mean age was 74.95 ± 8.79 years. The mean LogMar visual acuity (VA) was 0.16 ± 0.18 (early-stage: 0.12 ± 0.17, intermediate-stage: 0.19 ± 0.18, P = 0.122). Between early and intermediate AMD, no significant differences were seen in SCP and DCP vascular perfusion (P = 0.368, 0.859, respectively), FAZ (p = 0.836) and retinal thickness within the 6-mm area (P = 0.680). Drusen volume showed a significant difference (early-stage: 0.0706 ± 0.1272, intermediate-stage: 0.2102 ± 0.2211mm3, P < 0.01). Intermediate-stage AMD had significantly lower mean ChT (266.40 ± 115.55 vs. 204.97 ± 70.69 µm, P = 0.038) and CVI (0.605 ± 0.021 vs. 0.591 ± 0.015, P = 0.004) within the 5-mm area. Drusen volume was negatively correlated with ChT (r = -0.198, P = 0.017) and CVI (r = -0.209, P = 0.029). No significant correlation was found between drusen volume and VA (r = 0.051, P = 0.143), retinal thickness (-0.03, P = 0.393), FAZ (r = -0.023, P = 0.150), SCP (r = -0.011, P = 0.307), and DCP (r = -0.022, P = 0.190).

Conclusion: Drusen volume, a key AMD severity marker, correlates more strongly with choroidal parameters like ChT and CVI than retinal thickness and perfusion. It may serve as a biomarker for dry AMD severity, with choroidal biomarkers showing earlier disease changes.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JAS: Avista Therapeutics, Tenpoint, Code C (Consultant/Contractor), Clinical Trials: Gensight, SparingVision, Meira, Code F (Financial Support), Netramind Innovations, Gensight, Sparing Vision, Avista, Tenpoint, Prophesee, Chronolife, Tilak Healthcare, SharpEye, Cilensee, Vegavect, Code O (Owner), Allotopic Expression, Rod-derived Cone Viability Factor and related patents., Code P (Patent), Patent Royalties, Gensight, Code R (Recipient), Observer: Gensight, SparingVision, Avista, Vegavect. President: Fondation Voir et Entendre, Paris; President: StreetLab, Paris., Code S (non-remunerative); JC: Netramind Innovations, Code O (Owner). KKV: Netramind Innovations, Code O (Owner). SCB: Netramind Innovations, Code O (Owner).

Similar articles

See all similar articles

References

    1. Sadeghi E, Valsecchi N, Ibrahim MN, Du K, Davis E, Bollepalli SC, et al. Three-Dimensional Choroidal Vessels Assessment in Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2024;65:39. - PMC - PubMed
    1. Sadeghi E, Vupparaboina SC, Bollepalli SC, Vupparaboina KK, Agarwal K, Sahel J-A, et al. Incidence and risk factors of fellow-eyes wet conversion in unilateral neovascular age-related macular degeneration over 15-year follow-up. Graefe Arch Clin Ophthamol. 2024;263:77–86. - PubMed
    1. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharm Rep. 2006;58:353–63. - PubMed
    1. Taylor TRP, Menten MJ, Rueckert D, Sivaprasad S, Lotery AJ. The role of the retinal vasculature in age-related macular degeneration: a spotlight on OCTA. Eye. 2024;38:442–9. - PMC - PubMed
    1. Friedman E, Krupsky S, Lane AM, Oak SS, Friedman ES, Egan K, et al. Ocular blood flow velocity in age-related macular degeneration. Ophthalmology. 1995;102:640–6. - PubMed

MeSH terms

LinkOut - more resources